For virtual pharmaceutical organizations, successfully advancing a drug through clinical trials represents a significant milestone. But the work doesn’t end there as the transition from the clinical to commercial manufacturing phase introduces an entirely new set of operational challenges. As these organizations prepare for regulatory approval and product commercialization, the need for greater visibility, coordination, communication and control over external manufacturing partners becomes increasingly important.
Traditional pharmaceutical manufacturers built and maintained their own manufacturing plants and processes to build pharma products. Alternatively, virtual pharma organizations typically outsource much, if not all, of their manufacturing operations to Contract Manufacturing Organizations (CMOs). This approach allows companies to minimize capital expenditures, access specialized and experienced manufacturing expertise, and focus internal resources on drug development and commercialization.
However, outsourcing manufacturing does not allow pharmaceutical companies to relinquish their responsibility regarding product quality, regulatory compliance, inventory management, or supply chain performance.
As drug candidates progress through the clinical phase, managing these responsibilities becomes increasingly more difficult. Organizations must move beyond informal communication methods and establish processes that provide timely, accurate information across their external manufacturing networks.
How Manufacturing Requirements Changeas Clinical Trials Progress
During the early-stage clinical trial phase (specifically, Phase 1), manufacturing requirements are often relatively limited. The volumes produced are smaller, manufacturing schedules may be less frequent and structured, and organizations mostly focus on producing enough clinical trial material to support ongoing studies.
At this stage, communication between pharmaceutical companies and their CMOs may be managed through very informal processes like emails, spreadsheets, periodic meetings, and shared documents. Compliance-related controls are not considered at this point.
Although these approaches may be sufficient for smaller operations, they become increasingly difficult to manage as drugs move to the next clinical phase.
By Phase 2 and Phase 3 clinical trials, manufacturing requirements often expand considerably. Organizations may need to coordinate larger production campaigns, manage multiple manufacturing partners, monitor material availability, and prepare for potential commercial production. All of these processes must be done in a controlled, repeatable manner.
The transition to the commercialization phase introduces additional requirements, including:
- Increased manufacturing volumes and production frequency.
- More complex inventory management across multiple locations utilized as part of the drug’s supply chain.
- More visibility into batch traceability and product genealogy.
- Coordination of source materials, intermediates, and finished drug products.
- More extensive regulatory documentation and quality oversight.
- Improved demand forecasting and production planning.
- Greater visibility into manufacturing schedules, delays, and potential supply disruptions.
Without centralized access to manufacturing information, virtual pharmaceutical companies may struggle to maintain the operational visibility needed to support these growing responsibilities.
Read Also: Why Spreadsheets and Emails Are No Longer Enough for Virtual Pharma Manufacturing
The Challenges of Managing Multiple Contract Manufacturers
Virtual pharmaceutical organizations frequently rely on one or many external partners throughout the manufacturing process.
For example, one of the pharma organization’s CMOs may manufacture the active pharmaceutical ingredient (API), another may handle drug product formulation, and a third may provide packaging and labeling services.
Each manufacturing partner most likely will maintain its own systems,reporting procedures, and communication methods. The following is an example:
Consider a virtual pharmaceutical company preparing to launch its first commercial product.
Its API manufacturer maintains inventory records in one system, its drug product manufacturer provides weekly production updates through spreadsheets, and its packaging partner communicates scheduling changes through email.
When the pharmaceutical company needs to determine whether there is enough finished product that will be available for an anticipated launch, employees must gather information from multiple sources and reconcile the results. Inefficiency at its finest.
If an API shipment is delayed, that information may not immediately reach the drug product manufacturer or packaging partner. Consequently, production schedules may remain unchanged until the disruption becomes more significant.
This fragmented approach creates unnecessary operational risk.
As manufacturing networks expand, pharmaceutical companies need a more structured and controlled approach to coordinating information across their CMOs. Relying on fragmented, inconsistent processes can introduce significant compliance risks and raise concerns during regulatory inspections by agencies such as the FDA, particularly regarding data integrity, traceability, and accountability.
Why Inventory Visibility Becomes Critical Before Commercialization
Inventory management represents one of the most significant challenges for virtual pharmaceutical companies approaching commercialization.
During the clinical phase, inventory requirements are often driven by anticipated patient enrollment, clinical site demand, and study timelines.
Commercial manufacturing introduces additional complexities, including demand forecasts, safety stock requirements, product expiration dates, and distribution schedules.
Pharma organizations must understand not only how much inventory exists, but also where it is located, whether it is available for use, and when additional inventory will be required.
For example, a pharmaceutical company may believe that sufficient API inventory is available to support an upcoming manufacturing campaign based on a spreadsheet received from its CMO two weeks earlier.
However, some of that inventory may have been consumed during another production campaign, placed on quality hold, or allocated to another manufacturing requirement.
Without timely inventory updates, the pharmaceutical company may discover the shortage only after production planning has already begun.
The resulting disruption could delay manufacturing, increase procurement costs, and potentially affect product availability. Visibility into the CMOs inventory is of paramount importance.
Greater visibility into inventory quantities, material status, expiration dates, and manufacturing requirements helps organizations make more informed supply chain decisions.
Regulatory Compliance Requires More Than Outsourcing
One of the most important considerations for virtual pharmaceutical organizations is understanding that outsourcing manufacturing activities does not relinquish their role as being an integral part of the regulatory process.
The FDA's guidance on contract manufacturing arrangements emphasizes the importance of clearly defined responsibilities between pharmaceutical organizations and their manufacturing partners. Quality agreements should establish expectations for manufacturing activities, documentation, quality control, and communication.
As organizations prepare for commercial manufacturing, these responsibilities become particularly important.
For example, a CMO may identify a deviation during the production of a commercial batch. The pharmaceutical company needs to understand the nature of the deviation, its potential impact on product quality, and whether corrective actions are required.
If this information is communicated through disconnected emails and attachments, reviewing the investigation and coordinating decisions can become unnecessarily difficult.
A centralized approach to manufacturing oversight can help organizations maintain better visibility into quality-related information, monitor outstanding activities, and ensure that appropriate personnel have access to relevant documentation.
Importantly, better information sharing supports regulatory oversight but does not replace formal quality management processes, approved quality agreements, or the responsibilities of each organization's quality unit.
Read Also: Why Pharma Companies Struggle with Compliance (And How toFix It)
Real-World Examples Demonstrate the Importance of Manufacturing Oversight
Manufacturing disruptions are not simply theoretical risks.
In 2023, shortages of the chemotherapy medications cisplatin and carboplatin demonstrated how problems at a manufacturing facility can affect the broader pharmaceutical supply chain.
According to a U.S. Government Accountability Office report, cisplatin entered shortage after a manufacturer suspended operations at a facility to address quality issues identified during an FDA inspection. The disruption contributed to increased demand for carboplatin, which other manufacturers struggled to meet.
Although this example does not specifically involve a virtual pharmaceutical company, it illustrates how manufacturing quality issues and limited production capacity can create significant downstream consequences.
For a smaller virtual pharma organization that relies heavily on one or two CMOs, the consequences of an unexpected manufacturing disruption could be especially significant.
Consider another example involving a company transitioning a biologic therapy from clinical development to commercial manufacturing.
During clinical trials, the company may have manufactured relatively small batches at a specialized facility. As commercialization approaches, production must be scaled up, manufacturing processes transferred or qualified as needed, and additional supply chain partners coordinated.
A delay in equipment qualification, raw material delivery, or manufacturing documentation could affect the overall commercialization timeline.
The FDA's process validation framework recognizes manufacturing as a lifecycle activity involving process design, process qualification, and continued process verification.
For virtual pharmaceutical organizations, maintaining visibility across these activities is essential to identifying potential problems before they threaten critical milestones.
Moving From Reactive Communication to Proactive Manufacturing Oversight
Many virtual pharmaceutical companies rely on their CMOs to provide updates about production schedules, inventory availability, and manufacturing performance.
The problem is that these updates are often reactive.
A pharmaceutical company may learn about a production delay only after requesting a status report. Inventory discrepancies may not become apparent until monthly reconciliation. Documentation issues may remain unresolved until a scheduled quality review.
As organizations approach commercialization, this reactive approach becomes increasingly difficult to sustain.
Better CMO oversight requires a shift toward more consistent and structured information sharing.
Rather than waiting for periodic updates, pharmaceutical companies should establish processes that allow them to monitor important manufacturing activities, identify potential disruptions, and coordinate decisions with external partners.
This includes improving visibility into production schedules, inventory status, material requirements, and manufacturing documentation.
It also means establishing clearer accountability for outstanding activities and ensuring that relevant information is available to the appropriate stakeholders.
The objective is not to eliminate communication between pharmaceutical companies and their CMOs. Instead, it is to make those communications more efficient, transparent, and actionable.
How Slingshot Pharma's CMO Portal Improves Manufacturing Oversight
As virtual pharmaceutical companies transition from clinical development to commercialization, the ability to manage external manufacturing relationships becomes increasingly important.
Slingshot Pharma's new CMO Portal is designed to address many of the challenges associated with coordinating manufacturing activities across external partners.
Rather than relying on disconnected spreadsheets, emails, and periodic reports, the portal provides a centralized environment for exchanging manufacturing information between pharmaceutical companies and their CMOs.
Through improved access to relevant operational information, virtual pharmaceutical companies can gain greater insight into manufacturing activities without needing to manage multiple disconnected sources of information.
The CMO Portal helps organizations improve oversight in several importantareas.
Improved Manufacturing Visibility: Pharmaceutical companies can gain clearer insight into manufacturing activities, production requirements, and information shared by their CMOs. This helps reduce the uncertainty associated with managing external manufacturing operations.
Greater Inventory Transparency: Better access to CMO inventory information helps organizations understand material availability, monitor inventory requirements, and make more informed purchasing and production planning decisions.
Streamlined Communication and Collaboration: Centralizing manufacturing-related information reduces dependence on lengthy email chains and multiple spreadsheet versions, helping pharmaceutical companies and their CMOs work from more consistent information.
Improved Traceability and Accountability: When supported by appropriate system controls, centralized records, audit trails, and controlled access can help organizations track information changes and support their compliance processes.
Better Preparation for Commercial Manufacturing: As production volumes increase and manufacturing relationships become more complex, a structured approach to information sharing helps organizations manage growth without introducing unnecessary administrative complexity.
For virtual pharmaceutical companies preparing to commercialize their first product, these capabilities can provide an important operational foundation.
The transition from clinical trials to commercial manufacturing requires more than increased production capacity. It requires greater coordination, stronger oversight, and confidence that manufacturing information is accurate, accessible, and current.
By helping pharmaceutical companies establish a more connected relationship with their external manufacturing partners, Slingshot Pharma's CMO Portal supports the visibility and collaboration needed to navigate this transition.
Ultimately, the goal is simple: allow virtual pharmaceutical companies to focus more on bringing their therapies to market and less on chasing information from their manufacturing partners.
Learn more about Slingshot Pharma and how its pharmaceutical ERP solutions support manufacturing and supply chain operations.
.png)